JAZZ Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals develops and markets specialty pharmaceutical products focused on sleep disorders, oncology, and neuroscience, including treatments for narcolepsy and leukemia. Sector: Healthcare.

Jazz Pharmaceuticals PLC (JAZZ) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

On a capital return basis, ROIC is 18.02%, WACC is 5.37%, and the economic spread is 12.65%. On balance, ROIC clears WACC by a meaningful margin, suggesting the company is creating rather than consuming intrinsic value. Supporting metrics show ROE at 0.69% and ROA at 3.59%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company with credible compounding capacity if current operating execution persists.

On valuation, the company registers trailing P/E of 259.73, forward P/E of 9.66, PEG of 0.18. Forward P/E is considerably lower than trailing, which indicates earnings estimates are pointing higher — a dynamic that makes current prices look more reasonable on a prospective basis. The PEG reading suggests the market is pricing growth conservatively — a dynamic that can be favorable if earnings estimates prove accurate. A current ratio of 2.04 suggests the the company have sufficient short-term liquidity without excess. Taken together, the multiple and liquidity picture suggests a company that is priced for a constructive outcome — but where execution against earnings estimates will be the key determinant of whether that price is justified.

Stripping to unit economics, gross margin sits at 89.75%, operating margin at 24.84%, and free cash flow margin at 27.19%. Gross margins are exceptional, reflecting strong pricing power and a defensible cost structure. The operating margin reading is constructive, suggesting management teams are managing overhead costs effectively. The company's free cash flow margin is exceptional, pointing to capital-light businesses with strong reinvestment optionality. Read in combination, these margins suggest a business model that protects profitability across multiple cost layers.

Connecting operational trends with market expectations, TTM revenue growth of 19.06% indicating steady top-line growth at the company level, while the estimated 12-month price change of 3.84%, where consensus projections imply only modest price appreciation from current levels. At 2589.3%, the projected 12-month EPS growth rate is strong enough to be a primary driver of the forward investment case rather than a peripheral supporting detail. Operating momentum and analyst expectations are related but distinct — the former is backward-looking by nature, the latter inherently speculative. Against that backdrop, the more durable question is whether operating trends can be sustained long enough for analyst expectations to be validated. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The aggregate picture across capital efficiency, valuation, growth, and cash generation builds a compelling case.

This assessment is based solely on the quantitative metrics presented above and does not constitute financial advice. Investors should consider their own risk tolerance and conduct independent research before making investment decisions.